Identified main genetic variants involved in response to HIV

	Tweet

This international collaboration has been the largest ever to have taken place in a large scale study on genetic differences between patients infected by HIV, and is the first study of this kind in the field of infectious disease. Catalan participants have been coordinated by Javier Martínez-Picado, ICREA research professor in the Foundation irsiCaixa of Hospital Germans Trias i Pujol, and Josep M. Miró, consultant of the Unit of Infectious Diseases and AIDS of Hospital Clínic-IDIBAPS of Barcelona, and had the collaboration of Hospital de la Santa Creu i Sant Pau, and Hospital Mútua de Terrassa.

Research has been conducted with the latest genomics and bioinformatics technologies, analysing 550,000 variations of the complete human genome in 486 patients, mostly European, preselected from 30,000 potential candidates.

These variations, known as simple nucleotide polymorphisms (SNPs), are single variations affecting only one nucleotide or base of the genomic sequence. Despite humans sharing 99.9% of the genome sequence, there are still 3 million genetic variations –which make us different from one another– 90% of which are due to SNPs. Hence, a good knowledge of these variations is highly valuable for the determination of the progression of AIDS.

During the present study, obtained genetic data was compared to blood virus load in patients during the first two years after the infection, and also to the rhythm of immune degradation as a result of the infection. This type of comparison, known as association study, permitted to deduct main genetic variations playing a central role in the control of viral infection.

Results point to two gene variants related to the immune system. More precisely, these variations are in a genetic region responsible for the determination of immune response capacity against a number of infectious diseases, including AIDS. These variations are located in the short arm of chromosome 6 in genes controlling HLA-B and HLA-C molecular systems, responsible for the activation of the immune system so that it is able to locate and destroys cells infected by HIV. This study has also identified a third genetic variation involved in immune damage of patients, particularly in a gene encoding a protein which seemingly participates in viral replication, and is also located in chromosome 6.

Genetic variants associated to genes encoding HLA-B and HLA-C molecular systems would explain up to 15% of viral load variation among patients, whereas the third genetic variation would explain 5.8% of these differences. Further study of other genetic regions involved in this process is needed. Nevertheless, HLA-B variation presents the highest correlation with the immune response described until now.

Obtained information will be very useful in the long road to a more rational vaccine development. This and similar studies should push us toward more personalised medicine, where the most suitable drugs for each individual would be determined on the basis of their gene characteristics.

Researchers participating in this study have been coordinated by Amalio Telenti, co-director of the Institute of Macrobiology of the University of Lausanne, Switzerland, and by David Goldstein, director of the Center for Population Genomics and Pharmacogenetics of the Duke Institute for Genome Sciences and Policy, US. This project is framed within the context of the international consortium CHAVI (Center for HIV-AIDS Vaccine Immunology; http://www.chavi.org), born in July 2005 with the aim to conduct research on new vaccine strategies against HIV. Subsequently, European research groups and one Australian group joined this project with the name EuroCHAVI, and have developed, in coordination to the Duke Institute, the present study. The article concerning this project will be published in Science (paper edition) in August 2007.

Further information please contact:
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Communication Department
Marc de Semir, Head of Communication ()
Àlex Argemí, Sientific writer ()
Tel.: + 34 93 227 57 00

RELATED STORIES:
FDA Advisory Panel Approves Home HIV Test Kit   FDA Approves New In-Home HIV Test   Home HIV test advances   Survey Reveals Support for Over-the Counter HIV Testing   F.D.A. Panel Weighs Preventive Use of H.I.V. Drug   Stem Cell Therapy Shows Promise in Fight Against HIV   Progress against HIV thwarted by patients’ unmet needs   California to test pill for HIV prevention   Mechanism of HIV spread has potential for future drug therapy   Seeking HIV treatment clues in the neem tree   HIV Prevention Pill’s Value Varies by Target   Using AIDS drugs to prevent infection: a bargain?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]